---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-207549"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:50:38.528519+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TScan Q1 2026 revenue $1.0M, net loss $28.7M, cash funds into H2 2027

## Summary
- Revenue $1.0M vs $2.2M Q1 2025; net loss $28.7M vs $34.1M; R&D expenses $21.9M down from $29.8M.
- Cash and equivalents $128.1M plus $5M restricted cash, funding operations into second half of 2027.
- Phase 3 study of TSC-101 planned to start Q2 2026; early Cohort C data expected Q2 2026.
- Phase 1 trial of TSC-102-A01/A03 targeting CD45 to initiate in second half of 2026.

## SEC filing metadata
- accession: 0001193125-26-207549
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/0001193125-26-207549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/tcrx-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-207549
- JSON: https://secwatch.observer/filing/0001193125-26-207549.json
- Plain text: https://secwatch.observer/filing/0001193125-26-207549.txt

## Source-grounded claims
- claim_id: 44268958e3a7f90ef58aa18a18b7fe4303c56b9f
  claim: TScan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $1.0 million, net income $28.7 million.
  evidence_excerpt: Revenue: Revenue for the first quarter of 2026 was $1.0 million, compared to $2.2 million for the first quarter of 2025. The decrease was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen. R&D Expenses: Research and development (R&D) expenses for the first quarter of 2026 were $21.9 million, compared to $29.8 million for the first quarter of 2025. The decrease of $7.9 million was primarily driven by the timing in the purchase of supplies and consumables, as well as savings in connection with the Company’s previously announced strategy to prioritize the clinical development of its heme program. R&D expenses included non-cash stock compensation expense of $1.2 million and $1.7 million for the first quarter of 2026 and 2025, respectively. G&A Expenses: General and administrative (G&A) expenses for the first quarter of 2026 were $8.2 million, compared to $8.6 million for the first quarter of 2025. The decrease of $0.4 million was pr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/0001193125-26-207549-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.